Elevated plasma osteopontin associated with gastric cancer development, invasion and survival

Gut

Volumn 56, Issue 6, 2007, Pages 782-789

  Wu, Chun Ying ^b,c,d   Wu, Ming Shiang ^a   Chiang, En Pei ^e   Wu, Cheng Chung ^c   Chen, Yi Ju ^c   Chen, Chien Jen ^f   Chi, Nai Hui ^c   Chen, Gran Hum ^c   Lin, Jaw Town ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS;

ADENOCARCINOMA; AGED; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249775191     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.109868     Document Type: Article

References (43)

1. Gordon D. Luk. Tumors of the stomach. In: Feldman M, ed, Gastrointestinal and liver disease:pathophysiology, diagnosis, management.Philadelphia:WB Saunders, 2005:733-57.
2. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-55.
3. Kim JP. Surgical results in gastric cancer. Semin Surg Oncol 1999;17:132-8.
4. Miller FH, Kochman ML, Talamonti MS, et al. Gastric cancer. Radiologic staging. Radiol Clin North Am 1997;35:331-49.
5. Lee S, Baek M, Yang H, et al. Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett 2002;184:197-206.
6. Fukui R, Nishimori H, Hata F, et al. Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer. J Surg Res 2005;129:94-100.
7. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
8. Sun XJ, Zuo WS, Ma H, et al. [Expression of osteopontin mRNA and its clinical significance in gastric cancer]. Zhonghua Zhong Liu Za Zhi 2005;27:292-5.
9. Zhang DT, Yuan J, Yang L, et al. [Osteopontin expression and its relation to invasion and metastases in gastric cancer]. Zhonghua Zhong Liu Za Zhi 2005;27:167-9.
10. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-82.
11. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
12. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
13. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.
14. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
15. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91.
16. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 2002;287:1671-9.
17. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
18. Shimada Y, Watanabe G, Kowamura J, et al. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005;68:285-92.
19. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001;19:4245-51.
20. Wu MS, Wu CY, Chen G, et al. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003;104:617-23.
21. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
22. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001;41:723-49.
23. Zhu B, Suzuki K, Goldberg HA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 2004;198:155-67.
24. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000;83:156-63.
25. Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 200, 24:1749-58.
26. Lin YH, Huang CJ, Chao JR, et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol 2000;20:2734-42.
27. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
28. Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999;18:4237-46.
29. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004;279:11051-64.
30. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35.
31. Rangaswami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2005;280:19381-92.
32. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
33. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006;118:2255-61.
34. Bramwell VH, Tuck AB, Wilson SM, et al. Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 2005;4:1336-41.
35. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6:757-64.
36. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005;11:6459-65.
37. Boldrini L, Donati V, Dell'Omodarme M, et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005;93:453-7.
38. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85.
39. Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncog 1993;4:95-114.
40. Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95:506-12.
41. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12:3337-43.
42. Takemoto M, Tada K, Nakatsuka K, et al. [Effects of aging and hyperlipidemia on plasma osteopontin level]. Nippon Ronen Igakkai Zasshi 1999;36:799-802.
43. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-8.